Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 6/20 | 0.78 |
| ▸ | HEXB | P07686 | 6/20 | 0.78 |
| ▸ | DHFR | P00374 | 7/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12368255 | 0.88 | HEXA (1.00) | HEXAHEXBDHFRREN | |
| SCHEMBL3502224 | 0.80 | DHFR (0.78) | HEXAHEXBDHFR | |
| SCHEMBL12368245 | 0.75 | HEXA (0.77) | HEXAHEXBDHFR | |
| SCHEMBL12368260 | 0.74 | HEXA (0.79) | HEXAHEXBDHFR | |
| SCHEMBL6348834 | 0.73 | HEXA (0.77) | HEXAHEXBDHFR | |
| SCHEMBL12368264 | 0.72 | HEXA (0.77) | HEXAHEXBDHFR | |
| SCHEMBL12368268 | 0.71 | HEXA (0.73) | HEXAHEXBDHFRREN | |
| SCHEMBL6049641 | 0.71 | HEXA (0.70) | HEXAHEXBDHFRREN | |
| SCHEMBL11592534 | 0.71 | HEXA (1.00) | HEXAHEXBDHFR | |
| SCHEMBL16966518 | 0.69 | HEXA (0.59) | HEXAHEXBDHFRRENADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | HOSPITAL FOR SICK CHILDREN (CA) | 2015-10-01 | — | — | US | disclosed |
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | HOSPITAL FOR SICK CHILDREN (CA) | 2015-10-01 | — | — | US | disclosed |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | GAA, GBA1, MAN2B1 | HEXA 48/4885HEXB 59/4885DHFR 960/4885 |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | GAA, GBA1, MAN2B1 | HEXA 48/4885HEXB 59/4885DHFR 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.